Mustafa Özdoğan, MD X Hesabı İstatistikleri

X Hesabı

http://x.com/ozdogan_md

Son Kontrol : 28.06.2026

Takipçisi 6.642

Takip Edilen 1.037

Sektör

Tweetler	Beğeni	Retweet	Etkileşim
The FDA has approved sacituzumab govitecan for first-line triple-negative breast cancer (TNBC) in two settings: as monotherapy for patients not eligible for immunotherapy, and with pembrolizumab for PD-L1–positive disease. This expands a Trop-2...	19	11	%0,95
The FDA has approved palbociclib in combination with trastuzumab ± pertuzumab and endocrine therapy for maintenance treatment of HR+/HER2+ metastatic breast cancer. In the PATINA trial, this strategy improved median PFS from 29.1 to 44.3 months (HR...	13	13	%0,98
@elonmusk @midjourney There are no scientific articles, clinical data, sensitivity/specificity figures, regulatory status, or restrictions whatsoever. Just hype-filled promises...	0	0	%0,00

Tweetler	Tarih	Beğeni	Retweet	Etkileşim

Tweetler	Tarih	Beğeni	Retweet	Yorum	Görüntülenme

Takipçi : 6.642

Web sitesi : https://t.co/FcXlIA9hsE

Kullanıcı : ozdogan_md

Tanıtım :

Sayfa ile ilgili istek ve şikayetleriniz için aşağıdaki formu kullanabilirsiniz.